GynOnc15
TARGET AUDIENCE
This activity is intended for gynecologic and medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers. OVERVIEW OF ACTIVITY Existing and emerging multimodality treatment regimens used in the routine management of these diseases necessitate the physician’s working knowledge of novel surgical, radiation and systemic therapeutic techniques. Ongoing clinical trials will continue to refine the optimal management of these tumors, and the introduction of innovative, targeted compounds may offer individualized treatment options that provide increased efficacy and improved tolerability. In order to offer optimal patient care — including the option of clinical trial participation — clinicians who care for patients with gynecologic cancers must be well informed of these advances. These video proceedings from a CME symposium held during the Society of Gynecologic Oncology’s 2015 Annual Meeting on Women’s Cancer feature discussions with leading researchers with an expertise in gynecologic oncology regarding actual patient cases and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies for various gynecologic cancers. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Deborah K Armstrong, MD Advisory Committee: Eisai Inc; Contracted Research: Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech BioOncology, Incyte Corporation, MedImmune Inc, VentiRx Pharmaceuticals Inc; Other Remunerated Activities: Abbott Laboratories, Sanofi. Ursula A Matulonis, MD Advisory Committee: Momenta Pharmaceuticals Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP; Unpaid Consultant: AstraZeneca Pharmaceuticals LP. Bradley J Monk, MD Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Advaxis Inc, Cerulean Pharma Inc, Genentech BioOncology, GlaxoSmithKline, Gradalis Inc, Merck, Roche Laboratories Inc, TESARO Inc, Verastem Inc; Contracted Research: Amgen Inc, Array BioPharma Inc, Genentech BioOncology, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Novartis Pharmaceuticals Corporation, TESARO Inc; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc. Richard T Penson, MD, MRCP Consulting Agreements: Advance Medical - Health Care Management Services, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Vascular Biogenics Ltd; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Endocyte Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Vascular Biogenics Ltd. MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Nanostring Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Myriad Genetic Laboratories Inc. Hardware/Software Requirements: Last review date: July 2015 |